New shoulder implant shows promise in early study

NCT ID NCT04968405

Completed Disease control Sponsor: Catalyst OrthoScience Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a new shoulder implant called the Catalyst CSR System in 87 people with shoulder arthritis or bone damage. The implant is designed to preserve more natural bone than traditional replacements. Researchers measured pain, movement, and implant safety over two years. The goal was to see if the device performs well and is safe for everyday use.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Catalyst CSR Total Shoulder System (a bone-preserving shoulder implant)
What this could lead to: If successful, this implant could offer a less invasive option for shoulder replacement, potentially preserving more bone and improving recovery.
What could go wrong: This is a small, completed study with no control group, so results may not apply to everyone. Implant risks include infection, loosening, or need for revision surgery.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AVASCULAR NECROSIS OF THE HEAD OF HUMERUS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

avascular necrosis osteoarthritis osteonecrosis rheumatoid arthritis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

AVASCULAR NECROSIS OF THE HEAD OF HUMERUS OSTEOARTHRITIS SHOULDER RHEUMATOID ARTHRITIS SHOULDER

Contacts and locations

Locations

Beaumont Hospital Royal Oak

Royal Oak, Michigan, 48073, United States
Kaiser Permanente Northwest Center for Health Research

Portland, Oregon, 97227, United States
Lifespan/University Orthopedics

Providence, Rhode Island, 02914, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.